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ABSTRACT
Original Article
Background and Objectives
Cancer testis antigens (CTA) provide attractive targets for cancer-specific immunother-
apy. Although CTA genes are expressed in some normal tissues, such as the testis,
this immunologically protected site lacks MHC I expression and as such, does not
present self antigens to T cells. To date, CTA genes have been shown to be expressed
in a range of solid tumors via demethylation of their promoter CpG islands, but rarely
in chronic myeloid leukemia (CML) or other hematologic malignancies.
Design and Methods
In this study, the methylation status of the HAGE CTA gene promoter was analyzed by
quantitative methylation-specific polymerase chain reaction (MSP) and sequencing in
four Philadelphia-positive cell lines (TCC-S, K562, KU812 and KYO-1) and in CML sam-
ples taken from patients in chronic phase (CP n=215) or blast crisis (BC n=47). HAGE
expression was assessed by quantitative reverse transcriptase-polymerase chain
reaction.
Results
The TCC-S cell line showed demethylation of HAGE that was associated with over-
expression of this gene. HAGE hypomethylation was significantly more frequent in BC
(46%) than in CP (22%) (p=0.01) and was correlated with high expression levels of
HAGE transcripts (p<0.0001). Of note, in CP-CML, extensive HAGE hypomethylation
was associated with poorer prognosis in terms of cytogenetic response to interferon
(p=0.01) or imatinib (p=0.01), molecular response to imatinib (p=0.003) and progres-
sion-free survival (p=0.05).
Interpretations and Conclusion
The methylation status of the HAGE promoter directly correlates with its expression in
both CML cell lines and patients and is associated with advanced disease and poor
outcome.
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Chronic myeloid leukemia (CML) is a clonal dis-ease of the hematopoietic stem cell, in which areciprocal translocation, t(9;22)(q34;q11), forms
the Philadelphia chromosome (Ph’) and creates a new
fusion gene, BCR-ABL. This chimeric gene is translated
into a 210 kDa protein (p210), which has abnormal
tyrosine-kinase activity that is central to the pathogene-
sis of the disease.1 Treatment of CML has been notably
improved by imatinib mesylate, a potent tyrosine-
kinase inhibitor that blocks the kinase activity of p210,
thus inhibiting proliferation of Ph’-positive progenitors.2
In the past 5 years, the results of imatinib treatment of
CML have established this drug as the first-line therapy
for CML patients.3 However, both the persistence of
molecular disease in most imatinib-treated patients, as
well as the observation that discontinuation of the drug
usually results in a rapid loss of the response, indicate
that it is unlikely that imatinib alone can cure CML.2,3
An alternative attempt to target CML cells is an
active, specific immunotherapy (e.g. a vaccine). In fact,
because of the unique amino acid sequence of p210 at
the fusion point, the protein is a tumor-specific antigen
to which an immune response can be induced. In some
studies it has been shown that peptides derived from
the p210 fusion point (b3a2) can bind to several HLA
class I and class II molecules and thus generate peptide-
specific dendritic cells (DC) and cytotoxic T lymphocyte
(CTL) responses in vitro.4,5 Preliminary clinical data sug-
gest that the addition of a b3a2-specific vaccine to b3a2-
CML patients treated with conventional treatment
might favor a further reduction of residual disease,
therefore increasing the number of patients who reach a
molecular response.6 In disagreement with these find-
ings, it has been recently found that the CTL induced by
DC transfected with RNA extracted from BCR-ABL-
positive K-562 cells or CML blasts do not recognize epi-
topes derived from the chimeric BCR-ABL fusion pro-
tein. In contrast, they were able to lyse autologous DC
electroporated with RNA from patients with acute
myeloid leukemia (AML), indicating that some antigens
shared by these malignant cells are involved and recog-
nized by these CTL.7 Therefore, BCR-ABL is processed
and presented by Ph’-positive cells but is not the immu-
nodominant antigen that induces CD8+ T lymphocytes
in competition with other tumor-associated antigens.
However, the nature of these possible antigens is
unknown.
Among the tumor antigens that are presented to
human CTL by HLA class I molecules, several constitute
safe targets for immunotherapy because they are absent
in normal tissues. An important category of such tumor-
specific antigens are those encoded by the cancer testis
antigen (CTA) genes, such as the MAGE, BAGE, CAGE,
GAGE, HAGE, LAGE, PAGE, NY-ESO-1, SSX, and SCP
gene families.8 These genes are expressed in several
types of tumors but not in adult tissues with the excep-
tion of spermatogonia, which do not carry HLA mole-
cules and therefore cannot present antigens to the T
cells. Despite the fact that these antigens are expressed
in a broad range of human tumors, few CTA genes are
expressed in hematologic malignancies, although SCP1
and, specially,HAGE have been found in a proportion of
samples from both AML and CML patients.9,10
Epigenetic events appear to represent the unique mech-
anism regulating the expression of CTA in cancer cells,
and DNA methylation seems to play the major role; in
fact, a correlation between hypomethylated CpG dinu-
cleotides in CTA promoters and their expression has
been found in neoplastic cell lines and tissues.11-14
Moreover, unmethylated MAGE promoters drive the
transcription of reporter genes in CTA-negative neo-
plastic cells, suggesting that availability of transcription-
al factors is not involved in the heterogeneity of CTA
expression and that DNA methylation is the main
restricting factor for CTA expression.15 Consistently, in
vitro methylation of these reporter constructs is suffi-
cient to block their transcriptional activity in MAGE-
positive cells.16 In addition, all CTA genes that are
expressed in tumors or testis can be induced in vitro by
DNA demethylation or by inhibitors of histone
deacetylation.17
We have recently shown that sense and antisense
transcription of the LINE1 retrotransposon (one of the
most frequent repetitive sequences in the genome) is
activated by promoter hypomethylation in CML and
that this event is frequently associated with evolution of
the disease to the advanced phase.18 Since global
hypomethylation is consistently associated with
hypomethylation of the LINE1 elements,19 it can be ten-
tatively speculated that this genome-wide hypomethy-
lation could lead to the reactivation of genes silenced by
DNA methylation in CML patients, as for example,
CTA genes. In the present study, we provide the first
evidence showing the role of promoter methylation in
the primary regulation of HAGE and its role in the pro-
gression and clinical behavior of CML.
Design and Methods
Cell lines and samples
Four human Ph’-positive CML cell lines (K562,
KU812, KYO-1 and TCC-S) were obtained from the
American Type Culture Collection (Manassas, VA,
USA). The cells were cultured in appropriate medium
until harvested for extraction of DNA and RNA.
Heparinized bone marrow cells were collected from
patients with chronic phase CML (CP-CML), and from
healthy marrow donors. Immediately after harvest,
total white blood cells were obtained by dextran sedi-
mentation or by red cell lysis of centrifuged buffy coat
preparations. Mononuclear cells were isolated from
patients with CML in blast crisis (BC-CML) and donors
by sedimentation on Ficoll-Hypaque gradients. More
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than 90% of the mononuclear cell populations from
patients with acute phase CML were leukemic blasts.
We studied 215 patients with Ph-positive CP-CML,
diagnosed between August 1982 and December 2005.
The patients were unselected with regard to the type of
front-line therapy (39 patients received oral chemother-
apy alone, 76 interferon plus cytarabine and 100 ima-
tinib). A diagnostic sample in CP was available for all
patients. Paired samples, when both a CP diagnostic
sample and a BC sample were available, were analyzed
in 47 patients (34 in myeloid BC and 13 in lymphoid
BC). BC was defined by the presence of at least 30%
blasts in the blood or bone marrow or extramedullary
involvement. Risk categories according to the Sokal and
Hasford score systems were determined as previously
described.20,21 Hematologic, cytogenetic and molecular
responses to interferon and imatinib were evaluated. A
complete hematologic response (CHR) was defined by a
white cell count of less than 101×109/L, with no imma-
ture cells and less than 5% basophils in the peripheral
blood, a platelet count of less than 450×109/L, and the
absence of palpable splenomegaly or extramedullary
involvement. Cytogenetic response (CgR) was assessed
by G-banding in at least 20 cells in metaphase per sam-
ple and was defined as major CgR, including complete
responders (CCgR, 0% Ph’-positive metaphases) and
partial responders (PCgR, 1%-34% Ph’-positive meta-
phases) or poor CgR, including minor (MinCgR, 35%-
94% Ph’-positive metaphases) or no response (NCgR,
95%-100% Ph’-positive metaphases).
Disease progression was defined by any of the fol-
lowing events, whichever came first: (i) death from any
disease-related cause during treatment, (ii) the develop-
ment of accelerated-phase CML (defined by the pres-
ence of at least 15% blasts in the blood or bone marrow,
at least 30% blasts plus promyelocytes in the blood or
bone marrow, ≥20% peripheral basophils, or thrombo-
cytopenia <100×109/L unrelated to treatment), (iii) blast-
phase CML (defined by the presence of at least 30%
blasts in the blood or bone marrow or extramedullary
blastic involvement), iv) loss of complete hematologic
response (defined by the appearance of any of the fol-
lowing findings in two blood samples obtained at least
1 month apart: a white-cell count >20×109/L, a platelet
count ≥600×109/L, the appearance of extramedullary
disease, the appearance of at least 5% myelocytes and
metamyelocytes in the peripheral blood, or the appear-
ance of blasts or promyelocytes in the peripheral blood),
v) loss of major cytogenetic response (defined as ≥30%
increase in the Ph’-positive cells in two studies per-
formed at least 1 month apart), or vi) an increasing
white-cell count (defined as a doubling of the count to
more than 2×109/L on two occasions at least 1 month
apart in a patient who had never strictly had a complete
hematologic response despite the maximum tolerated
doses of therapy).
Minimal residual disease was determined during fol-
low-up using a standardized real-time quantitative
reverse transcriptase–polymerase chain reaction (PCR)
analysis on peripheral blood and/or marrow aspirate, as
established in the framework of the EU concerted
action.22 Complete molecular remission (CMR) was
defined as negative quantitative PCR confirmed by nest-
ed PCR for BCR-ABL. Major molecular response (MMR)
was defined as a reduction in the BCR-ABL/ABL ratio of
at least three logs with regard to the diagnostic baseline
value. Some of the patients in the present study (n=140)
had been previously typed for hypomethylation of
LINE1 retrotransposons.18
Semiquantitative real time methylation-specific PCR
(qrt-MSP) of HAGE promoter and exon 1
Analysis of theHAGE promoter and exon 1 (GeneBank:
NM_018665) has revealed that HAGE possesses a 383bp
CpG island located between nt48 and nt430, showing
>60% C+G content and an observed-over-expected CpG
frequency of >0.6. Promoter methylation of the HAGE
gene was determined by the MSP method, as previously
reported.23 Briefly, 1 µg of genomic DNA was denatured
by treatment with NaOH and modified by sodium bisul-
fite. Qrt-MSP was performed as previously reported by
our group18 in a rapid fluorescent thermal cycler with
three-color fluorescence monitoring capability (Light-
Cycler, Roche), using 1 µL of bisulfite-modified DNA in a
10 µL reaction volume with 0.4 µmol/L of each primer,
and 1 µL of 1× LightCycler FastStar DNA Master SYBR
Green I (Roche Molecular Biochemicals). The final Mg2+
concentration in the reaction mixture was adjusted to 3.5
mmol/L. Amplification of the HAGE methylated
sequences was used as target sequence (forward, 5’-
GGAGGAGTTTTTAAGGTTTTTACGT-3’; reverse, 5’-
GACAATTCCTCGTAACCAACG-3’). The following
program conditions were applied for running the qrt-
MSP: denaturation program, one cycle at 95°C for 10 min-
utes; amplification program, 45 cycles at 95°C for 10 s,
65°C for 10 s and 72°C for 10 s; melting program, one
cycle at 95°C for 0 s, 40°C for 60 s and 90°C for 0 s; and
cooling program, one cycle at 40°C for 60 s. The temper-
ature transition rate was 20°C/s, except in the melting
program, in which it was 0.4°C/s between 40°C and
90°C. Amplification of the HAGE unmethylated
sequences for each sample was performed as the refer-
ence sequence (forward, 5’-GGAGGAGTTTTTAAG-
GTTTTTATGT-3’; reverse, 5’-ACAACAATTCCT-
CATAACCAACAA-3’). It was amplified in the same run
and following the same procedure described above for
methylated sequences. A procedure based on the relative
quantification of target sequence (methylated sequences)
vs their controls/calibrators in relation to the reference
sequence (unmethylated sequences) was used to assesses
the degree of HAGE promoter methylation. Calculations
were automatically performed by the LightCycler soft-
ware (RealQuant, version 1.0, Roche). The normalized
ratio was obtained from the following equation and
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expressed as a percentage of the control/calibrator:
Normalized ratio (NHAGE-METHYLATION)=(Etarget)∆Cp target (control– sam-
ple) ÷ (Eref)∆Cp ref (control–sample)
The efficiency (E) of each gene was calculated from
the slope of the crossover points (Cp) versus DNA con-
centration plot, according to the formula E=10(-1/slope).
∆Cp corresponded to the difference between
control/calibrator Cp and sample Cp, for either the tar-
get or the reference sequences. The selected control/cal-
ibrator was the bone marrow specimen from a healthy
donor, which was considered as 100% (this is not an
absolute value indicating a fully methylated patient but
a relative value used as a measure for the relative level
of HAGE methylation in the particular sample). Water
blanks were included with each assay. Results were
confirmed by repeating bisulfite treatment and MSP
assays for all samples. Occasionally, equal amounts of
PCR products were separated on a 2% agarose gel,
stained with ethidium bromide, and visualized under
UV light.
Expression of HAGE transcripts
Qrt-PCR for HAGE expression was performed with
the LightCycler technology, using 1 µL of cDNA in a 20
µL reaction volume with 0.4 µmol/L of each primer (for-
ward: 5’-CCTTTCAATGTTATCCTGAG-3’; reverse:
5’- TATTCTTCAGATTGACGAAG-3’), and 2 µL of 10×
LightCycler FastStar DNA Master SYBR Green I (Roche
Molecular Biochemicals). The Abelson gene (ABL1) was
employed as the reference gene, and it was amplified in
the same run and following the same procedure
described above (forward: 5’-CCCAACCTTTTC-
GTTGCACTGT-3’; reverse: 5’-CGGCTCTCGGAG-
GAGACGTAGA-3’). In order to reduce the variation
between different assays and samples, a procedure
based on the relative quantification of target genes ver-
sus their controls/calibrators in relation to the reference
gene was used. Calculations were automatically per-
formed by LightCycler software (RealQuant, version
1.0, Roche). The normalized ratio (NHAGE-EXPRESSION),
expressed as a percentage of the control/calibrator, was
obtained by RealQuant software as described above for
qrt-MSP of the HAGE promoter. The selected
controls/calibrators were bone marrow specimens from
healthy donors, which were considered as having 100%
expression.
5-aza-2'-deoxycytidine treatment
CML-derived K562, KU812, KYO-1 and TCC-S cell
lines were grown at a density of 750,000 cells/mL in 25
cm2 flasks with 8 mL of RPMI 1640 medium supplement-
ed with 20% fetal bovine serum and maintained at 37°C
in a humid atmosphere containing 5% CO2. Each of the
cell lines was treated with 2 and 4 µM of 5-aza-2'-deoxy-
cytidine (Sigma-Aldrich, Steinheim, Germany) for 4 days.
HAGE promoter and exon 1 analysis by sequencing
after sodium bisulfite modification
The methylation status of HAGE promoter and exon 1
was analyzed by bisulfite genomic sequencing of its CpG
island in TCC-S and KU812 CML derived cell lines. One
microgram of genomic DNA was treated and modified
using the CpGenomicTM DNA Modification Kit (Intergen
Company, Purchase, NY, USA). Bone marrow DNA from
healthy donors was used as a methylated or positive con-
trol for sequencing analysis. After bisulfite modification,
the HAGE promoter was amplified by seminested-PCR.
The first PCR was performed using 5 µL of modified
DNA and HAGE1-SB1 (5´-TTTTTTTTGGAATAAT-
GTTTTATTA-3´) and HAGE1-SB2 (5´-TAACCCCACC-
TATCCTACCCTAC-3´) primers under the following con-
ditions: 94°C for 10 min, 35 cycles at 94°C for 1 min,
52°C for 1 min and 72°C for 1 min, and a final elongation
cycle at 72ºC for 10 min. The second PCR was performed
with 5 µL of the first PCR product using HAGE1-SB3 (5´-
GGAGGAGTTTTTAAGGTTTTTA-3´) and HAGE1-SB2
primers under the following conditions: 94°C for 10 min,
20 cycles at 94°C for 1 min, 52°C for 1 min and 72°C for
1 min, and a final elongation cycle at 72ºC for 10 min.
Two PCR reactions were carried out in a total volume of
25 µL, with 1 U high fidelity Platinum Taq DNA poly-
merase (Invitrogen Life Technologies, Paisley, UK), 1.5
mM MgCl2, 0.2 mM dNTP and 50 pmol of each primer.
The second 280 bp PCR products were separated on a 2%
agarose gel, stained with ethidium bromide and visual-
ized under UV light. Amplification products obtained in
the second PCR reaction were subcloned into pCR® 4-
TOPO® plasmid using TOPO TA Cloning® Kit for
sequencing (Invitrogen Life Technologies, Paisley, UK)
and transformed into Escherichia coli according to the man-
ufacturer’s recommendations. Colonies with recombinant
plasmids containing the described PCR products were
screened by digestion with EcoR I (Amersham Biosciences,
Buckinghamshire, UK). Candidate plasmid clones were
sequenced with ABI-PRISMTM d-Rhodamine Terminator
Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA, USA) in an ABI PRISMTM 377 DNA Sequencer
(Applied Biosystems, Foster City, CA, USA) using T7 and
T3 universal forward and reverse primers.
Statistical analysis
All calculations were performed with the SPSS statisti-
cal package (SPSS, Chicago, IL, USA). The medians, stan-
dard deviations (SD) and interquartile ranges for age and
the most relevant clinical and laboratory findings at diag-
nosis were calculated for patients with and without
HAGE hypomethylation and tested for any significant dif-
ferences with the Mann-Whitney U test (for continuous
variables) or χ2 analysis and Fisher’s exact test (for cate-
gorical variables). Overall survival (OS) was calculated
from time of diagnosis to death from any cause and was
censored only for patients known to be alive at last con-
tact. Progression-free survival (PFS) was measured from
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the diagnosis of CML to the appearance of BC or death
without disease progression, and was censored only for
those patients alive and without evidence of progression
at last follow-up. For calculations of both OS and PFS,
bone marrow transplant recipients were censored at the
time of transplantation. Distributions of OS and PFS
curves were estimated by the method of Kaplan and
Meier, with the 95% confidence intervals being calculat-
ed using Greenwood’s formula. Comparisons of OS and
PFS between groups were based on the log-rank test.
Comparisons adjusted for significant prognostic factors
were based on Cox regression models and hazard regres-
sion models. All progression and survival data were
updated as of March 31, 2006, and all follow-up data
were censored at that date.
Results
HAGE is hypermethylated in normal bone marrow cells
We analyzed HAGE methylation in 30 normal bone
marrow samples. As expected, HAGE promoter DNA
sequences were strongly methylated in normal bone
marrow cells. This is illustrated by the amplification of
the methylated sequences with the complete lack of
non-methylated sequence amplification in half of these
samples (Figure 1A). However, 50% of the non-neoplas-
tic marrow specimens displayed a slight amount of
HAGE hypomethylation, as defined by the presence of
specific products in the melting curves from both
methylated (melting temperature 76.1ºC) and unmethy-
lated sequences (melting temperature 74.6ºC, Figure 1B
and 1C). Based on the background fluorescence intensi-
ty, a cut-off level was determined for specific fluores-
cence for both unmethylated and methylated sequences
in normal individuals. This threshold was used to calcu-
late the cycle threshold or crossing point (CP) of each
sample. The CP value was directly proportional to the
amount of target sequence present in the sample. The
normal sample which showed the lowest difference in
CP between the target (methylated sequences) and the
reference (unmethylated sequence) sequences was used
as the control/calibrator sample for quantification of
HAGE promoter methylation in both healthy individu-
als and CML samples. It was considered as 100%.
Based on these prerequisites and to determine the cut-
off value for altered HAGE promoter methylation in
CML samples, the methylation status of the HAGE pro-
moter was quantified by means of qrt-MSP in the
healthy donors showing some degree of unmethylated
sequence amplification. NHAGE-METHYLATION ratios fell
between 100% and 217% (160± 40%). A NHAGE-METHYLATION
ratio equal or below 80% (determined as the mean
minus 2 SD) was chosen to define hypomethylation of
HAGE promoter in CML DNA samples.
HAGE is hypomethylated in CML samples
By qrt-MSP, the CpG island of the HAGE promoter
was revealed to be highly hypomethylated in the TCC-
S Ph-positive CML cell line (NHAGE-METHYLATION ratio: 10%)
whereas K562, KYO-1 and KU812 cell lines showed
normal levels of HAGE methylation (median NHAGE-METHY-
LATION ratio: 98%, range: 100-97%, Figure 2 and Table 1).
In order to confirm the results of the qrt-MSP, we
screened bone marrow DNA from healthy donors and
two CML-derived cell lines (TCC-S and KU812) using
bisulfite genomic sequencing. As described in theDesign
and Methods section, the 280 bp amplification products
of the HAGE promoter obtained in a second PCR,
which are composed of 20 CpG dinucleotides, were
subcloned and sequenced. Genomic sequencing after
bisulfite modification revealed that bone marrow DNA
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Figure 1. Methylation status of the HAGE promoter in healthy indi-
viduals and in a patient with CML. (panel A) MSP analysis of the
CpG island within the HAGE promoter in healthy individuals and
CML patient. BC indicates blast crisis CML; UM, unmethylated
sequences; M, methylated sequences. (panel B) qrt-MSP melting
curve analysis of a sample from a CML patient showing the pres-
ence of two specific PCR products: unmethylated (dotted line,
melting temperature 74.6ºC) and methylated HAGE sequences
(solid line, melting temperature 76.1ºC) (panel C) HAGE promoter
methylation level of a representative CML case (lines with trian-
gles) and a control/healthy individual (lines with circles) as meas-
ured by qrt-MSP. The difference between the crossing points of the
methylated (bold lines) and unmethylated (fine lines) HAGE
sequences was smaller for the CML patient than for healthy indi-
vidual, indicating a higher level of hypomethylation in the CML
patient.
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Figure 2. Methylation status of the HAGE promot-
er in Ph’-positive CML cell lines. MSP analysis of
the CpG island within the HAGE promoter in four
Ph’-positive CML cell lines. UM, unmethylated
sequences; M, methylated sequences. Only the
TCC-S cell line showed HAGE hypomethylation.
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from healthy donors and DNA from the KU812 CML-
derived cell line were almost completely methylated,
showing methylation of the 20 analyzed CpG dinu-
cleotides in all analyzed clones. In contrast, the TCC-S
cell line showed a complete lack of methylation of
HAGE promoter in all analyzed CpG dinucleotides and
clones (Figure 3).
Among CML patients, hypomethylation of HAGE
promoter was more frequently observed in BC (22/47,
46%) than during CP disease (47/215, 22%), with this
difference being statistically significant (p=0.01).
Furthermore, a more profound level of hypomethyla-
tion was observed in BC than in CP samples (mean NHAGE-
METHYLATED ratios: 16%±5% vs 32%±8%, p=0.06). There
was a significant concordance between HAGE hypo-
methylation and presence of LINE1 hypomethylation;
HAGE hypomethylation was present in 23 of 93 (25%)
LINE1 methylated tumors versus 24 of 47 (52%) LINE1
hypomethylated tumors (p=0.01).
HAGE hypomethylation in CML is associated with
over-expression of HAGE transcripts
Quantitative expression of HAGE transcripts was
assessed by means of qrt-PCR using cDNA from a
healthy donor as the control (considered to have a NHAGE-
EXPRESSION ratio of 100%). Normalized ratios for HAGE
expression were determined in bone marrow specimens
from 30 healthy individuals. NHAGE-EXPRESSION ratios fell
between 20% and 100% (mean NHAGE-EXPRESSION: 35±25%).
Among CML patients, those with methylated HAGE
promoter showed a mean NHAGE-EXPRESSION of 34%±30%,
similar to that found in healthy individuals; however,
the mean NHAGE-EXPRESSION was significantly higher in those
CML patients who showed HAGE promoter
hypomethylation (319%±118%, p<0.0001). An NHAGE-
EXPRESSION value equal or above 160% (determined as the
mean NHAGE-EXPRESSION from normal individuals plus 5 SD)
was chosen to define over-expression of HAGE in CML
RNA samples. Using this cut-off value, over-expression
of HAGE was found in 100% of CML patients with
HAGE hypomethylation and in none of the CML
patients with methylated HAGE promoter (p<0.0001).
High levels of HAGE expression were observed in the
HAGE hypomethylated TCC-S cell line (NHAGE-EXPRESSION
ratio: 1045%) whereas HAGE hypermethylated Ph-pos-
itive CML (K562, KU812 and KYO-1) cell lines showed
low levels of HAGE expression (mean NHAGE-EXPRESSION
ratio: 10%, range: 0-20%, Table 1).
Exposure of CML cell lines to the demethylating
agent 5-aza-2'-deoxycytidine restored expression of
HAGE mRNA in cell lines that show hypermethylation
of the HAGE promoter, such as K562, KU812 and KYO-
1 (mean NHAGE-EXPRESSION ratio: 160%, range: 142-178%) but
had no effect on HAGE mRNA expression in the
hypomethylated CML-derived TCC-S cell line (Table 1).
These results indicate that hypermethylation is a major
mechanism through whichHAGE expression is silenced
in CML cells.
HAGE hypomethylation, response to treatment and
clinical outcome
The clinical and laboratory characteristics at diagnosis
of CP-CML patients with hypomethylated and normal
HAGE at diagnosis are shown in Table 2. Individual fac-
tors such as sex, age, spleen size, percentage of blast
cells in the peripheral blood, platelet count, hemoglobin
level and white cell count were not significantly associ-
ated with the HAGE methylation status. When HAGE
methylation status was correlated with pretreatment
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Table 1. HAGE methylation status and mRNA expression in Ph’-
positive CML cell lines before and after treatment with 5-aza-2’-
deoxycytidine.
Cell NHAGE-METHYLATION HAGE NHAGE-EXPRESSION NHAGE-EXPRESSION p
line hypomethylation + AZA
Tcc-s 10% yes 1045±72% 1129±63% 0.8
K562 98% no 10±1% 178±12% 0.01
Kyo-1 97% no 20±2 % 160±14% 0.02
Ku812 100% no 0% 142±11% 0.003
NHAGE-EXPRESSION represents the mean expression ± SD in cell lines from three
different experiments in comparison with expression in healthy bone marrow
cells (normalized ratio = 100%).
Figure 3. Analysis of HAGE1 CpG island methylation status by
bisulfite sequencing in bone marrow of healthy donors, TCC-S and
KU812 CML derived cell lines. (Panel A) Schematic description of
the HAGE CpG island. Long black arrow indicates the HAGE trans-
lation start site and each vertical bar represents a CpG dinu-
cleotide. The gray arrows show the location of the MSP primers
and the black arrows the location of bisulfite sequencing primers
(A: HAGE1-SB1 primer; B: HAGE1-SB2 primer; C: HAGE1-SB3
primer). (Panel B) Bisulfite sequencing of the HAGE CpG island.
Each box indicates a CpG dinucleotide (white box: unmethylated,
black box: methylated) and each line represents the analysis of 20
CpG dinucleotides of a single clone of an HAGE analyzed region.
1: non-modified sequence of HAGE1 CpG island; 2: methylated
sequence of HAGE CpG island after bisulfite modification; 3: non-
methylated sequence of HAGE CpG island after bisulfite modifica-
tion. *CpG dinucleotide position.
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risk groups, no significant association between HAGE
hypomethylation and high-risk patients, as assessed by
the Sokal and Hasford scoring systems, was found. In
the present study, CML patients were treated with oral
chemotherapy (mainly, hydroxyurea, n=39), interferon-
based regimens (n=76) or imatinib (n=100). Thirty-
seven patients received stem cell transplantation (5
autologous, 32 allogeneic). The treatment modality and
number of patients who received transplantation were
similarly distributed between the two HAGE methyla-
tion groups (Table 2). Moreover, mean time of interfer-
on administration was similar in methylated (31
months) and hypomethylated (30.4 months) patients.
Hypomethylation of the HAGE promoter was correlat-
ed with a poor response to treatment (Table 2). Thus,
the CHR rate was significantly lower among
hypomethylated patients than in patients with methy-
lated HAGE promoter (72% versus 89%, p=0.05).
Among 76 patients under interferon therapy, a CCgR
was observed in 28% of those with methylated HAGE
and in none of the hypomethylated patients (p=0.01).
Among the 100 CP-CML patients receiving imatinib as
front-line therapy, the rates of complete cytogenetic
response at 6 and 12 months were 66% and 90% in the
HAGE methylated group, as compared with 23% and
55% in the HAGE hypomethylated group (p=0.01 and
p=0.02, respectively). In addition, the major molecular
response rate at 12 months was better for patients with
methylated HAGE (58%) than for HAGE hypomethy-
lated patients (18%, p=0.003). Moreover, the time to
achieve a CCgR was significantly longer for
hypomethylated patients (mean: 11.1±7.4 months) than
for methylated patients (mean: 7.3±3.3 months,
p=0.01).
Survival data were available from all patients. Kaplan-
Meier analysis revealed differences in the duration of
the CP among patients under interferon therapy (Figure
4). The estimated median PFS time for hypomethylated
patients was 72.2 months (95%CI [confidence interval],
42.6-101.5) compared to 112.6 months (95% CI, 87.8-
137.4) for patients with methylated HAGE (p=0.05).
Among patients receiving imatinib therapy, only two
patients progressed, both of whom had hypomethyla-
tion of the HAGE gene.
Discussion
In this study, we provide the first evidence that pro-
moter hypomethylation is the molecular mechanism
directly responsible for the high expression levels of the
HAGE gene in CML. We have demonstrated that HAGE
mRNA is expressed in 22 and 46% of CML patients in
chronic phase and blast crisis, respectively. HAGE
mRNA was previously reported to be expressed in half
of 43 CML patients at presentation.10 However, this
study did not verify the methylation status of theHAGE
promoter CpG islands. The evidence of HAGE expres-
sion, induced by hypomethylation, was provided by the
re-expression of HAGE, after treatment with 5-aza-2’-
deoxycytidine, in CML cell lines not expressing HAGE.
In addition, our results clearly indicate a significant cor-
relation between the expression and hypomethylation
of the CpG sites of HAGE. The methylation status
analysis of the HAGE promoter in CML cell lines and
patients showed a perfect correlation between the
expression of HAGE and hypomethylation.
Interestingly, the key finding of increasedHAGE expres-
sion in BC-CML with hypomethylated HAGE promot-
er seems to be contradicted by the fact that three out of
four CML cell lines had low or no detectable HAGE
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Table 2. Clinical characteristics at diagnosis and outcome of 215
chronic myeloid leukemia patients divided according to HAGE
methylation status.
Feature HAGE hypomethylated HAGE methylated p
(n=47) (n=168)
Sex (M/F), % 58/42 60/40 NS
Age, median (IQR) 48 (37-59) 49 (37-60) NS
Palpable spleen, % 69 63 NS
Median hemoglobin (g/L) 120 110 NS
(IQR) (96.7-129.1) (83.1-119.6)
WBCx109/L, median 162 143 NS
(IQR) (60.4-326.1) (52.1-226.5)
Median platelet count 372 400 NS
109/L (IQR) (262-614) (280-650)
Median peripheral blood 1 (0-4.2) 1 (0-3.8) NS
blast as % WBC (IQR)
Sokal score, % NS
High 35 27
Low/Intermediate 65 73
Hasford score, % NS
High 19 26
Low/Intermediate 81 74
Treatment type, % NS
Chemotherapy 22 17
Interferon 36 35
Imatinib 42 48
Transplantation 20 17
Response to treatment, %
CHR 72 89 0.05
CCgR with IFN 0 28 0.01
CCgR at 6m with IM 23 66 0.01
CCgR at 12m with IM 55 90 0.02
MMR at 12m with IM 18 58 0.003
Disease progression, % 53 62 NS
Death, % 42 55 NS
IQR: interquartile range; CHR: complete hematologic response;
CCgR: complete cytogenetic response; MMR: major molecular response;
IFN: interferon; IM: imatinib mesylate.
expression. However, we have observed18 that cancer
cell lines (including CML-derived cell lines) have an
increased rate of hypermethylation of certain CpG
islands and less global genomic hypomethylation.
Fortunately, some of them (TCC-S) retain the specific
epigenetic profile of each tumor cell type and are, there-
fore, very useful for in vitro experiments while not con-
tradicting the results obtained in clinical samples.
Recently, we showed that LINE1 sense and antisense
transcription was activated by promoter hypomethyla-
tion in CML and that this event was frequently associ-
ated with the evolution of the disease to an advanced
phase.18 Because LINE1 hypomethylation is an indicator
of global genomic hypomethylation and LINE1 under-
methylation is closely correlated with that observed in
the HAGE gene, we hypothesize that in CML,
demethylation of theHAGE gene occurs during progres-
sive stages of leukemogenesis in CML, probably after
global DNA hypomethylation, as seen in many
advanced cancers. Moreover, all these findings indicate
that hypomethylation is an important feature in CML.
Firstly, hypomethylation increased from non-neoplastic
marrow cells toward CML cells; secondly, an increase in
the hypomethylation status was observed in CML
patients with advanced disease; and finally, high levels
of hypomethylation would be a marker of poor progno-
sis in a subset of patients with CP-CML.
What could be the functional significance underlying
the hypomethylation of HAGE in CML? The transition
of CML from CP to BC is characterized by genomic
instability leading to the accumulation of molecular and
chromosomal abnormalities in addition to the Ph’-chro-
mosome.24 Several reports have shown that mammalian
DNA methylation plays an important role in maintain-
ing genomic stability unrelated to the effects of DNA
methylation on gene expression and that hypomethyla-
tion of DNA in tumor cells is associated with genomic
instability.25 Moreover, genomic hypomethylation caus-
es tumorigenesis in mice associated with the acquisition
of additional genomic changes.26 Our results suggest
that hypomethylation affecting not only repetitive
DNA sequences but also specific gene promoters (i.e,
CTA genes) could be one of the mechanisms employed
by CML cells to generate an unstable genome.
It is evident that HAGE hypomethylation occurs in
many BC-CML patients but whether this epigenetic
change is a cause or a consequence of the progression is
unclear. Our data argue against the second alternative
because HAGE hypomethylation was not only associat-
ed with BC but was also observed in a proportion of
CML patients in CP. Interestingly, these patients
responded slowly to treatment and progressed to BC
much more rapidly than CP patients lacking hypo-
methylation, suggesting that hypomethylated patients
ab initio may be more prone to genomic instability, sim-
ilarly to patients with deletions of the derivative chro-
mosome 9.27 In support of the role of this epigenetic
event in the progression of cancer, genome-wide
hypomethylation has been shown to increase progres-
sively in parallel to advanced grade in breast, ovarian,
cervical, and neural cancers28-30 and it has also been asso-
ciated with the progression of lung cancer.31 Therefore,
it is not surprising that CTA gene expression has also
been reported to be associated with less-differentiated,
higher-grade tumors, later stages of cancer, and worse
outcome.32-34 In fact,MAGEA3,MAGE-A10, andMAGE-
A1 promoters were shown to undergo progressive
demethylation in gastric cancer in parallel to disease
progression.35
On the other hand, although HAGE expression could
be a passive bystander in a more hypomethylated
genome, the HAGE gene (located on 6q12-q13) encodes
a protein that shows 55% similarity with the human
p68 protein, a DEAD-box protein which has been
demonstrated to have ATP-dependent RNA helicase
activity.36 The protein encoded by the HAGE gene
seems to be a new member of the family of DEAD-box
proteins,37which contain the highly conserved Asp-Glu-
Ala-Asp (D-E-A-D) motif. These proteins are involved
in many aspects of RNA metabolism, spermatogenesis,
embryogenesis, and cell growth, functioning as impor-
tant transcriptional regulators. The amino acids that are
highly conserved in all of the DEAD-box proteins are
also present in the HAGE protein, suggesting that
HAGE may also be an ATP-dependent RNA helicase.
DEAD-box proteins are up-regulated in cancer cells but
not in the corresponding normal cells/tissues.38 In addi-
tion, it has been recently reported that expression of an
uncharacteristically large proportion of genes involved
in pre-mRNA processing (including RNA helicases) is
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Figure 4. Kaplan-Meier progression-free survival curve for CML
patients. PFS curve according to the HAGE methylation status for
76 CML patients treated with interferon. Solid line, patients with
methylated HAGE; dashed line, patients with hypomethylated
HAGE.
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increased in primary p210BCR/ABL-positive CD34+
cells, which correlates with altered splicing of gene
products.39 Taken together, these data suggest that
HAGE is involved in both altered gene expression and
RNA editing. One can, therefore, speculate that CML
cells that overexpress HAGE may have a selective
advantage over HAGE-negative cells, which would pro-
vide an explanation for why HAGE expression is posi-
tively selected during CML progression, even though its
presence elicits a cytotoxic T-cell-mediated immune
response. However, we have not performed functional
analyses and therefore, the possible role of HAGE in the
transformed status of CML cells should be clarified in
further studies.
Besides the possible role of the HAGE gene in the
pathogenesis and prognosis of CML, most CTA anti-
gens are immunogenic, and their use as therapeutic can-
cer vaccines is currently being evaluated.40,41 The DNA
methyltransferase inhibitor 5-aza-2’-deoxycytidine
(decitabine) has been used as part of chemotherapy pro-
tocols, primarily to reverse hypermethylation of tumor
suppressor gene promoters, and has been shown to be
beneficial in CML.42 This drug, capable of inducing
HAGE expression, could increase patient eligibility and
treatment effectiveness in CTA-targeted immunothera-
py. Our results suggest that the level of HAGE gene
expression increases as CML progresses. This in turn
suggests a potentially important therapeutic role for
CTA-based cancer vaccines in the management of the
late stages of CML that should be addressed in future
studies.
In conclusion, the results of the present study show
that the methylation status of the HAGE promoter
directly correlates with its expression status in CML cell
lines and patients and that in CML high levels of HAGE
transcripts are associated with advanced disease and
poor outcome.
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